Citigroup’s Arcturus Therapeutics ARCT Stock Holding History

Citigroup’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-24,000	Closed	-$407K	–	5558
2024 Q4	$407K	Buy	+24,000	New	+$452K	﹤0.01%	3973
2023 Q4	–	Sell	-29,000	Closed	-$741K	–	5688
2023 Q3	$741K	Buy	+29,000	New	+$893K	﹤0.01%	2756
2023 Q1	–	Sell	-35,000	Closed	-$594K	–	5477
2022 Q4	$594K	Buy	+35,000	New	+$610K	﹤0.01%	3045
2021 Q1	–	Sell	-25,100	Closed	-$1.09M	–	6230
2020 Q4	$1.09M	Buy	+25,100	New	+$1.7M	﹤0.01%	3458

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Citigroup's ARCT Position: Q2 2026 in Review

Citigroup increased its Arcturus Therapeutics (ARCT) stake by 460% in Q2 2026, buying an estimated $84.3K and bringing the position to 13,027 shares worth $87.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4759.

Citigroup first reported a position in ARCT in Q1 2014 and has held it in 45 quarters since. The position peaked at $4.86M in Q2 2021. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

Citigroup held 13,027 shares of Arcturus Therapeutics worth $87.5K as of Q2 2026.
Citigroup bought 10,700 Arcturus Therapeutics shares in Q2 2026, an estimated $84.3K.
Arcturus Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4759 holding.
Citigroup first reported a position in Arcturus Therapeutics in Q1 2014 and has held it in 45 quarters since.
Citigroup's Arcturus Therapeutics position peaked at $4.86M in Q2 2021.
135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.